Protalix Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Protalix Biotherapeutics, Inc. on November 12, 2013, regarding events occurring on November 7, 2013. The report details the results of the Company's 2013 Annual Meeting of Shareholders held in Carmiel, Israel.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes.
Material Changes and Voting Results
Holders of 51.9% of the Company's outstanding shares entitled to vote participated in the meeting. The following matters were voted upon:
- Election of Directors: Seven directors were elected. Notably, Roger D. Kornberg, Ph.D., received a significant number of votes withheld (20,405,839) compared to votes for (20,477,649), while other nominees received strong support with over 35 million votes "For" each.
- Executive Compensation: Shareholders approved, on a non-binding advisory basis, the compensation of the named executive officers with 35,555,681 votes "For" and 5,298,808 votes "Against".
- Auditor Ratification: The appointment of Kesselman & Kesselman was ratified with 48,123,804 votes "For" and 400,767 votes "Against".
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Key Facts for Investor Verification
- Verify the total number of outstanding shares to contextualize the 51.9% participation rate.
- Review the specific reasons for the high number of votes withheld for director Roger D. Kornberg, Ph.D.
- Confirm the tenure and background of the newly elected directors.
- Check subsequent filings for the Company's financial performance, as this 8-K contains no financial data.